Angle PLC
LSE:AGL

Watchlist Manager
Angle PLC Logo
Angle PLC
LSE:AGL
Watchlist
Price: 10.5 GBX -4.55% Market Closed
Market Cap: 33.9m GBX
Have any thoughts about
Angle PLC?
Write Note

Angle PLC
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Angle PLC
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Angle PLC
LSE:AGL
Income from Continuing Operations
-ÂŁ18m
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Smith & Nephew PLC
LSE:SN
Income from Continuing Operations
$305m
CAGR 3-Years
-18%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Income from Continuing Operations
$23.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-9%
EKF Diagnostics Holdings PLC
LSE:EKF
Income from Continuing Operations
ÂŁ5.1m
CAGR 3-Years
-32%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Creo Medical Group PLC
LSE:CREO
Income from Continuing Operations
-ÂŁ22.4m
CAGR 3-Years
-2%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Income from Continuing Operations
-$18.5m
CAGR 3-Years
-111%
CAGR 5-Years
-66%
CAGR 10-Years
N/A
No Stocks Found

Angle PLC
Glance View

Market Cap
33.9m GBX
Industry
Health Care

ANGLE Plc operates as a holding company, through its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 102 full-time employees. The company went IPO on 2004-03-17. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.

AGL Intrinsic Value
22.18 GBX
Undervaluation 53%
Intrinsic Value
Price

See Also

What is Angle PLC's Income from Continuing Operations?
Income from Continuing Operations
-18m GBP

Based on the financial report for Jun 30, 2024, Angle PLC's Income from Continuing Operations amounts to -18m GBP.

What is Angle PLC's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-7%

Over the last year, the Income from Continuing Operations growth was 19%. The average annual Income from Continuing Operations growth rates for Angle PLC have been -7% over the past three years .

Back to Top